Efficacy of Food Industry By-Product β-Glucan/Chitin-Chitosan on Lipid Profile of Overweight and Obese Individuals: Sustainability and Nutraceuticals.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 14 09 2024
revised: 04 10 2024
accepted: 06 10 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

Fat-binding nutraceutical supplements have gained considerable attention as potential cholesterol-lowering strategies to address dyslipidemia in overweight and obese individuals. This study aimed to evaluate the effects of a polysaccharide-rich compound containing β-glucan/chitin-chitosan (βGluCnCs) on lipid profiles and lipoprotein function. In a prospective, two-arm clinical trial, 58 overweight and obese individuals were randomized to receive either 3 g/day of βGluCnCs or a placebo (microcrystalline cellulose) for 12 weeks. Serum lipids and lipoprotein functions were assessed at baseline and at 4-week intervals throughout the study. The administration of βGluCnCs led to a significant increase in HDL cholesterol (HDLc) levels and improved HDLc/non-HDLc and HDLc/total cholesterol (TC) ratios, while reducing apolipoprotein B (ApoB) levels (

Identifiants

pubmed: 39408385
pii: nu16193420
doi: 10.3390/nu16193420
pii:
doi:

Substances chimiques

beta-Glucans 0
Chitosan 9012-76-4
Chitin 1398-61-4
Cholesterol, HDL 0
Lipids 0
Apolipoproteins B 0
Cholesterol, LDL 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CDTI Spanish Ministry of Competitiveness and Economy (MINECO)
ID : RTC-2016-5317-1
Organisme : MICINN-AEI
ID : AEI/10.13039/501100011033-[PID2019-107160RB-I00]
Organisme : Instituto Salud Carlos III (ISCIII)
ID : FISPI22/01930

Auteurs

Victoria Santisteban (V)

Institut Recerca Sant Pau, Sant Antoni Mª Claret 167, 08025 Barcelona, Spain.
School of Pharmacy and Food Sciences, University of Barcelona (UB), 08036 Barcelona, Spain.

Natàlia Muñoz-Garcia (N)

Institut Recerca Sant Pau, Sant Antoni Mª Claret 167, 08025 Barcelona, Spain.

Anallely López-Yerena (A)

Institut Recerca Sant Pau, Sant Antoni Mª Claret 167, 08025 Barcelona, Spain.

Montserrat Puntes (M)

Medicament Research Center (CIM), Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain.

Lina Badimon (L)

Institut Recerca Sant Pau, Sant Antoni Mª Claret 167, 08025 Barcelona, Spain.
Centro de Investigación Biomédica en Red Cardiovascular (CIBER-CV), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Cardiovascular Research Chair, Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.

Teresa Padro (T)

Institut Recerca Sant Pau, Sant Antoni Mª Claret 167, 08025 Barcelona, Spain.
Centro de Investigación Biomédica en Red Cardiovascular (CIBER-CV), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH